CHM ceases enrolment in Phase 1 trial and Company update
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The Safety Monitoring Committee determined that the current dose level is unsafe, leading to the halt of further patient dosing in accordance with the study protocol. Chimeric is also exploring funding options and negotiating with creditors to address financial uncertainties moving forward.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Trading Halt
- Application for quotation of securities - CHM
- Quarterly Activities/Appendix 4C Cash Flow Report
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- Investor Presentation
Later from Chimeric Therapeutics
- Appendix 4E and Preliminary Final Report
- FY2026 Annual Report, creditor update and Board changes
- Initial Director's Interest Notice - RM
- Final Director's Interest Notice - BG
- Final Director's Interest Notice - LR
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics